N

NewLimit

Develops epigenetic medicines to extend healthspan

Senior/Research Associate - Single Cell Technology

Translational Research & Bench BiologyConfirmed live in the last 24 hours
Full-timeSouth San Francisco, CA, USA$75k - $100kIn-person

About the Job

Requirements

  • A bachelor's degree in cell biology, molecular biology, or a related natural science, or equivalent industry experience.
  • At least 2 years of work experience in a cell or molecular biology laboratory in an academic or industry setting.
  • Experience with standard molecular biology workflows, including nucleic acid extraction, quantitative polymerase chain reaction, enzyme-linked immunosorbent assay, next-generation sequencing library construction, library quantification, and quality control.
  • Experience with necropsy, organ and tissue collection, primary tissue dissociation, mammalian cell culture, and sample processing, including single-cell suspension preparation, nuclei isolation, and fixation.

Responsibilities

  • Measure the biodistribution, pharmacokinetics, and efficacy of reprogramming medicines using traditional molecular assays and genomics methods.
  • Design and execute experiments involving the isolation, culture, and processing of cells, tissues, and organs for molecular profiling.
  • Collaborate with the Epigenetic Editing team to perform large-scale single-cell perturbation experiments with custom chemistries.
  • Perform single-cell profiling experiments to map epigenetic features of age-related disease and evaluate interventions.

Desired Qualifications

  • Experience with in vivo animal handling.
  • Experience with single-cell genomics methods, such as 10x Genomics, Parse Bio, Perturb-seq, CROProp-seq, or similar methods.
  • Experience troubleshooting or optimizing next-generation sequencing workflows.
  • Experience with flow cytometry sorting for single-cell preparations.

About the Company

NewLimit

Develops epigenetic medicines to extend healthspan

NewLimit develops medicines that aim to extend healthy years by reprogramming the epigenome of aging cells. It works by identifying aging-related epigenetic changes using single-cell genomics, machine learning, and high-throughput functional assays, then creating interventions to reverse those changes in targeted tissues such as the immune system and liver. Compared with others, NewLimit combines a specific focus on epigenetic reprogramming with a data-driven, tissue-targeted pipeline and pursues partnerships with pharma and biotech players to develop its proprietary medicines. Its goal is to deliver a new class of medicines that significantly increases the healthspan for patients with age-related diseases.

Company size
51-200
Company stage
Series C
Total funding
$650M
Headquarters
South San Francisco, CA
Founded
2022

Recently Posted Jobs

Explore more opportunities at NewLimit

See more jobs